Terms: = Lymphoma AND MYD88, Q99836, MYD88D, 4615 AND Treatment
203 results:
1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
2. [miR-515-5p targeting Toll-like receptor 4 regulates myeloid differentiation primary response gene 88/nuclear factor-kappa B pathway to inhibit apoptosis and inflammatory response of osteoarthritis chondrocytes].
Cai D; Yang Z; Zhong C; Zhang J; Hong S
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2024 Mar; 38(3):315-323. PubMed ID: 38500425
[TBL] [Abstract] [Full Text] [Related]
3. How to manage waldenström's macroglobulinemia in 2024.
Grunenberg A; Buske C
Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
[TBL] [Abstract] [Full Text] [Related]
4. A single-centre, real-world study of BTK inhibitors for the initial treatment of myd88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract] [Full Text] [Related]
5. A Rare Case of Non-IgM Lymphoplasmacytic lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.
Yin J; Bains A; Alsammak M; Fu JJ
Am J Case Rep; 2024 Mar; 25():e940963. PubMed ID: 38437184
[TBL] [Abstract] [Full Text] [Related]
6. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
8. A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse.
Yan X; Chen B; Jing H; Yang Z; Zhang T; Lin Y; Shi J
J Hematop; 2023 Dec; 16(4):235-240. PubMed ID: 38175437
[TBL] [Abstract] [Full Text] [Related]
9. Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the P53 signaling pathway and brain-gut axis.
Yue F; Zeng X; Wang Y; Fang Y; Yue M; Zhao X; Zhu R; Zeng Q; Wei J; Chen T
BMC Microbiol; 2024 Jan; 24(1):8. PubMed ID: 38172689
[TBL] [Abstract] [Full Text] [Related]
10. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
11. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
12. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract] [Full Text] [Related]
13. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to myd88
Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
[TBL] [Abstract] [Full Text] [Related]
14. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract] [Full Text] [Related]
15. MiR-525-5p inhibits diffuse large B cell lymphoma progression via the myd88/NF-κB signaling pathway.
Guo X; Zhang J; Zeng J; Guo Y; Zhao L
PeerJ; 2023; 11():e16388. PubMed ID: 37953776
[TBL] [Abstract] [Full Text] [Related]
16. In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
Brunner A; Thalhammer-Thurner GC; Willenbacher W; Haun M; Zelger BG; Willenbacher E
Ann Hematol; 2024 Feb; 103(2):553-563. PubMed ID: 37951851
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
Khwaja J; Vos JMI; Pluimers TE; Japzon N; Patel A; Salter S; Kwakernaak AJ; Gupta R; Rismani A; Kyriakou C; Wechalekar AD; D'Sa S
Br J Haematol; 2024 Jan; 204(1):177-185. PubMed ID: 37726004
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract] [Full Text] [Related]
19. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of genomic alterations in primary central nervous system lymphoma.
He X; Fan X; Shan Y; Ji X; Su L; Wang Y
Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032
[TBL] [Abstract] [Full Text] [Related]
[Next]
